Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04702841

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

Clinical Application of Chimeric Antigen Receptor Modified γδ T Cells（CAR - γ δ T Cells） in Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

Sponsor: Anhui Provincial Hospital

Conditions CAR Malignant Tumors

Interventions Chimeric antigen receptor modified γδ T cells

Updated 5 times since 2021 Last updated: Mar 4, 2021 Started: Jun 3, 2020 Primary completion: Jun 30, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04702841, this EARLY_PHASE1 trial focuses on CAR and Malignant Tumors and remains ongoing. Sponsored by Anhui Provincial Hospital, it has been updated 5 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown EARLY_PHASE1

Status: Unknown Status → Unknown
Apr 2023 — Jul 2024 [monthly]

Unknown Status EARLY_PHASE1

Status: Recruiting → Unknown Status
Apr 2021 — Apr 2023 [monthly]

Recruiting EARLY_PHASE1
Feb 2021 — Apr 2021 [monthly]

Recruiting EARLY_PHASE1

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anhui Provincial Hospital
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Data source: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hefei, China